Gonadorelin

Gonadorelin is structurally identical to endogenous GnRH, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. The critical pharmacological fact about it is that the pituitary responds to pulses, not to continuous exposure: intermittent dosing every 60 to 120 minutes reproduces normal physiology and stimulates gonadotropins, while continuous exposure downregulates the receptor and shuts the axis down - which is precisely how the depot GnRH agonists in this class achieve chemical castration. Because its half-life is only minutes, ordinary intermittent subcutaneous injection behaves as a pulse by default. In TRT practice it has largely replaced hCG in the US, though it is a genuinely weaker stimulus - it depends on a responsive pituitary, whereas hCG bypasses the pituitary entirely and acts straight on the testis.

Targets: GnRH receptor (GnRHR), Anterior pituitary gonadotrophs, LH, FSH

• · The most common compounded-pharmacy protocol in US TRT clinics. Some clinics use 50 to 100 mcg daily instead. Do not run it as a continuous infusion - that suppresses the axis rather than supporting it.
• · This is the licensed clinical use of pulsatile GnRH and requires a dedicated pump. It is highly effective for restoring ovulation and spermatogenesis in hypothalamic disease.
• · Distinguishes pituitary from hypothalamic causes of hypogonadism.

Work out your exact syringe units →

• commonInjection-site irritation— Usually a small transient welt.
• uncommonHeadache
• uncommonFlushing
• uncommonNausea or abdominal discomfort
• uncommonAxis suppression from over-frequent dosing— The mechanism is real - too-frequent or continuous dosing downregulates GnRH receptors and does the opposite of what you want.
• rareAnaphylaxis— Reported with repeated administration in the clinical literature.
• rareOvarian hyperstimulation with pump use— Relevant to pulsatile pump therapy in women, not to TRT-adjunct dosing.

• Hormone-sensitive tumours including prostate cancer - you are deliberately raising testosterone.
• Known hypersensitivity to GnRH or its analogues.
• Pregnancy.
• Undiagnosed abnormal vaginal bleeding.

• redundanthcg — Both aim at preserving testicular function on TRT. hCG bypasses the pituitary and is the stronger stimulus; gonadorelin is gentler and preserves more of the natural axis. Running both is usually pointless.
• synergyTestosterone replacement therapy — This is the whole use case - gonadorelin offsets the testicular atrophy that exogenous testosterone causes.
• conflictcetrorelix — A GnRH antagonist blocks exactly the receptor gonadorelin is trying to stimulate.
• conflictleuprolide — Depot GnRH agonists occupy and desensitise the same receptor, abolishing any gonadorelin response.

• · Total and free testosterone, LH and FSH at baseline and after 8 to 12 weeks.
• · Testicular volume by physical exam or orchidometer if maintenance is the goal.
• · Semen analysis if fertility preservation is the actual objective - testicular size is a poor proxy.

An approved drug historically (Factrel, Lutrepulse); most US brands are discontinued and it is now supplied almost entirely by compounding pharmacies on prescription. Also sold as a research chemical.

• Lutrepulse (gonadorelin acetate) prescribing information (label)
• Bhasin et al. 2018, Endocrine Society clinical practice guideline on testosterone therapy in men with hypogonadism (guideline)
• Santoro et al. 1986, pulsatile GnRH therapy for hypothalamic amenorrhoea, JCEM (trial)

The GnRH receptor is a Gq/11-coupled receptor on pituitary gonadotrophs, and it is famous for one structural oddity: it has no C-terminal cytoplasmic tail. That matters more than it sounds. The tail is where beta-arrestin normally docks to drive rapid internalisation, so the human GnRH receptor internalises slowly and resists acute desensitisation, which is precisely what allows the pituitary to respond to pulse after pulse for decades without going deaf. Agonist binding activates phospholipase C beta, generating IP3 and DAG, mobilising intracellular calcium and activating protein kinase C, which drives LH and FSH exocytosis within minutes and, on a slower timescale, transcription of the gonadotropin subunit genes. The single most important pharmacological fact about this receptor is frequency dependence. Pulses roughly every 60 to 120 minutes favour LH; slower pulses favour FSH; and continuous exposure, which is what a depot agonist produces, first floods the system in a flare and then downregulates receptor number and uncouples the signalling, shutting the axis off completely. Gonadorelin's two-to-ten-minute half-life means an ordinary intermittent injection is a pulse whether you intended it or not, and that is the whole basis of its use as a testicular-maintenance drug. It also sets the boundary of what it can do. Gonadorelin is a pituitary stimulus, so it requires an intact and responsive pituitary. On full testosterone replacement the hypothalamic-pituitary axis is suppressed at the source, and asking a suppressed gonadotroph for LH is a weaker proposition than hCG's approach of skipping the pituitary entirely and binding the Leydig cell receptor directly. That is the honest reason hCG has better data behind it, and gonadorelin displaced it in US clinics for regulatory and compounding-supply reasons rather than because anyone showed it worked better.

The characteristic failure is that nothing happens and it takes months to notice, because the man is also on testosterone replacement and his total testosterone looks fine regardless. Testicular volume is the endpoint people watch and it is a poor one - it can be maintained while spermatogenesis quietly fails. The second failure is dosing frequency. People reason that if two doses a week help, daily must help more, and daily approaches continuous, and continuous is how you chemically castrate someone. It is a shallow slope but it is real, and the mechanism is the same one leuprolide exploits deliberately. The third is product quality: gonadorelin degrades relatively quickly once reconstituted, several compounded preparations carry a beyond-use date well short of the four weeks people assume, and a vial that has been in a warm bathroom cabinet for six weeks may be doing nothing at all. The fourth is diagnostic laziness - gonadorelin is often started in men whose problem is primary testicular failure, where a pituitary stimulus was never going to work.

• GnRH receptor (GnRHR) on pituitary gonadotrophs — Native ligand affinity; specific Kd values were not resolved from a primary source here.

  Gq/11 coupling, phospholipase C activation, calcium mobilisation and PKC signalling, producing LH and FSH release within minutes. Frequency of stimulation determines whether LH or FSH is favoured, and continuous stimulation suppresses both.

• Leydig cells (indirect, via LH)

  Intratesticular testosterone production and preservation of testicular volume. Entirely downstream - gonadorelin never touches the testis itself.

• Sertoli cells (indirect, via FSH)

  Spermatogenic support. This is the arm that matters if fertility rather than testicular size is the real goal, and it is the arm that hCG alone does not supply.

• Testosterone Therapy in Men With Hypogonadism: Endocrine Society Clinical Practice Guideline Guideline · 2018

  Not a trial. Included because it is the document that defines what is and is not evidence-based in testosterone replacement, and gonadorelin as a routine TRT adjunct does not appear in it as a recommended therapy.

LH rises within 15 to 30 minutes of a dose and is back to baseline within a couple of hours - the entire pharmacological event is over before most people have left the bathroom. Testosterone follows any LH pulse by hours. Testicular volume changes are measured in weeks: expect eight to twelve weeks before a difference is apparent by orchidometer, and three to six months before semen parameters meaningfully move in either direction. There is no loading phase and no accumulation, so there is nothing to build toward.

Gonadorelin's entire reason to exist in the community is as an adjunct to testosterone replacement, and that is a genuine synergy in intent if a weakly evidenced one in practice. Running it alongside hCG is close to pointless: hCG already supplies a supraphysiological LH signal directly at the testis, so a marginal pituitary nudge underneath it adds nothing you can measure. If fertility is the goal rather than testicular size, the combination with real evidence is hCG plus recombinant FSH, not gonadorelin plus anything. Any GnRH antagonist - cetrorelix, ganirelix, degarelix - blocks the exact receptor gonadorelin is trying to stimulate and abolishes the response entirely. Depot agonists such as leuprolide, triptorelin or goserelin do the same thing by desensitisation rather than blockade, and once someone is on a depot, gonadorelin is inert. The one non-obvious interaction is with the timing of your own dosing: too-frequent gonadorelin, or an infusion, converts a stimulus into suppression, so more often is not more.

Against hCG for testicular maintenance, gonadorelin is the gentler and considerably weaker option. hCG bypasses the pituitary and binds the Leydig cell directly, which means it works regardless of how suppressed the axis is, and it has actual dose-ranging human data showing 250 IU every other day maintains intratesticular testosterone. Gonadorelin has no equivalent dataset. Its real advantages are that it produces far less oestradiol, preserves more of the natural pulse architecture, and does not carry hCG's Leydig-cell desensitisation risk at high doses. Its real disadvantage is that it depends entirely on a pituitary that exogenous testosterone has already switched off. Against kisspeptin, gonadorelin acts one level lower and is therefore the more direct stimulus. Against the depot GnRH agonists in this same class, gonadorelin is chemically the parent compound of all of them and pharmacologically their exact opposite in effect, purely because of how long it lasts.

$40–$120/month. US compounding pharmacies have typically supplied gonadorelin at roughly 50 to 120 dollars a month through telehealth TRT clinics, and research-chemical vials are cheaper. Availability has been unstable because of shifting FDA compounding rules, which is worth knowing before building a protocol around it. Figures are indicative and were not verified in this session.

• ?Volume of distribution, protein binding and formal clearance figures for gonadorelin were not sourced in this session, and the discontinuation of most branded products makes the original label data hard to retrieve.
• ?Subcutaneous bioavailability is unquantified.
• ?The entire twice-to-thrice-weekly TRT-adjunct protocol is extrapolated practice, not trial-derived. No randomised trial has compared gonadorelin against hCG or against nothing for testicular preservation on testosterone replacement.
• ?Whether the 100 to 250 mcg community dose produces a physiologically meaningful LH pulse in a man already suppressed by exogenous testosterone is genuinely unclear, and the published data to settle it do not exist.
• ?The tmax figure of about 30 minutes for subcutaneous dosing is inferred from the reported 10 to 40 minute subcutaneous half-life rather than measured directly.
• ?Compounded product stability and potency vary between pharmacies and are not independently verified.

• Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA, Journal of Clinical Endocrinology and Metabolism, 2018 · PMID 29562364

  The reference standard for what testosterone replacement should look like. Read it partly for what it does not say about gonadorelin.

• Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI, The Journal of Urology, 2013 · PMID 23260550

  Included on the gonadorelin page deliberately. This is the kind of human evidence that exists for hCG as a testicular-preservation strategy and does not exist for gonadorelin.

• Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, Sutton PR, Wright WW, Brown TR, Yan X, Zirkin BR, Jarow JP, Journal of Clinical Endocrinology and Metabolism, 2005 · PMID 15713727

  The dose-ranging study that quantified what it takes to keep a testis working under exogenous testosterone. The comparison every gonadorelin protocol is implicitly and unfavourably measured against.